|
|
|
|
Vol. 63, Issue 5, 973-982, May 2003
Institut National de la Santé et de la Recherche
Médicale (INSERM) U 531, Institut Louis Bugnard, CHU Rangueil,
Toulouse, France (C.G., J.T., C.E., L.P., D.F.); INSERM U 563, Département Innovation Thérapeutique et Oncologie
Moléculaire, Institut Claudius Regaud, Toulouse, France (M.P.);
Laboratoire de Chimie Théorique, Université de Nancy,
Vandoeuvre, Nancy, France (B.M.); Centre National de la Recherche
Scientifique-Unité de Recherche Associée 1845, Faculté de Pharmacie, Montpellier, France (J.M.); and Max Planck
Institute für Biochemie, Martinsried, Germany (L.M.).
The cholecystokinin (CCK) receptors CCK1R and CCK2R exert important
central and peripheral functions by binding the neuropeptide cholecystokinin. Because these receptors are potential therapeutic targets, great interest has been devoted to the identification of
efficient ligands that selectively activate or inhibit these receptors.
A complete mapping of the CCK binding site in these receptors would
help to design new CCK ligands and to optimize their properties. In
this view, a molecular model of the CCK2R occupied by CCK was built to
identify CCK2R residues that interact with CCK functional groups. No
such study has yet been reported for the CCK2R. Docking of CCK in the
receptor was performed by taking into account our previous mutagenesis
data and by using, as constraint, the direct interaction that we
demonstrated between His207 in the CCK2R and Asp8 of CCK (Mol
Pharmacol 54:364-371, 1998; J Biol
Chem 274:23191-23197, 1999). Two residues that had not
been revealed in our previous mutagenesis studies, Tyr189 (Y4.60) and
Asn358 (N6.55), were identified in interaction via hydrogen bonds with
the C-terminal amide of CCK, a crucial functional group of the peptide.
Mutagenesis of Tyr189 (Y4.60) and Asn358 (N6.55) as well as
structure-affinity studies with modified CCK analogs validated these
interactions and the involvement of both residues in the CCK binding
site. These results indicate that the present molecular model is an
important tool to identify direct contact points between CCK and the
CCK2R and to rapidly progress in mapping of the CCK2R binding site.
Moreover, comparison of the present CCK2R.CCK molecular model with that
of CCK1R.CCK, which we have previously published and validated, clearly
argues that the positioning of CCK in these receptors is different.
This article has been cited by other articles:
![]() |
M. Foucaud, E. Marco, C. Escrieut, C. Low, B. Kalindjian, and D. Fourmy Linking Non-peptide Ligand Binding Mode to Activity at the Human Cholecystokinin-2 Receptor J. Biol. Chem., December 19, 2008; 283(51): 35860 - 35868. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Marco, M. Foucaud, I. Langer, C. Escrieut, I. G. Tikhonova, and D. Fourmy Mechanism of Activation of a G Protein-coupled Receptor, the Human Cholecystokinin-2 Receptor J. Biol. Chem., September 28, 2007; 282(39): 28779 - 28790. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Paillasse, C. Deraeve, P. de Medina, L. Mhamdi, G. Favre, M. Poirot, and S. Silvente-Poirot Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation Mol. Pharmacol., December 1, 2006; 70(6): 1935 - 1945. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Foucaud, I. G. Tikhonova, I. Langer, C. Escrieut, M. Dufresne, C. Seva, B. Maigret, and D. Fourmy Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors Mol. Pharmacol., March 1, 2006; 69(3): 680 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204. [Abstract] [Full Text] [PDF] |
||||